1. Pink Sheet

340B Program Spending Continues To Swell In 2022, Topping $53bn

 
• By Cathy Kelly

Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.

pharmacy percentage
Hospital Use Of 340B Drug Discounts Expanding Rapidly • Source: Shutterstock

Outpatient drug purchases under the 340B discount program rose 22% to $53.7bn in 2022, according to new spending data released by the Health Resources and Services Administration. The upsurge continued a streak of 20%-plus annual increases in the program in recent years.

The spending figures were first released by Drug Channels Institute CEO Adam Fein on his Drug Channels blog after he obtained the data from HRSA through a Freedom of Information...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.